PFE
PFIZER INC
$25.62
-1.61%
$146.0B
No data for this timeframe.
Vol
Market Cap$146.0B
Cap SizeLarge Cap
Analyst ConsensusHold (42%)
Inst. Holders12 funds
Inst. Value$20.9B
Inst. Activity2 buys / 1 sells
Reddit Sentiment67° Warm
SEC Reports6
Congressional3 trades
Recent Activity
Aug 17, 2026
fda_pdufa
PDUFA: PFE — Padcev in muscle-invasive bladder cancer (MIBC) — 2026-08-17
FDA target action date 2026-08-17 for PFE (PFIZER INC). Drug: Padcev. Indication: muscle-invasive bl
Jun 4, 2026
Event
Premarin
WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER and PROBABLE DEMENTIA WARNING:
May 29, 2026
Insider
BOURLA ALBERT sold 23 shares
Chairman & CEO @ $26.18 ($602.14)
May 16, 2026
SEC
Argus Research upgrades PFE to Buy — PT $35 (+35%) amid 8-firm cluster; consensus remains cautious
ANALYST-UPGRADE — Impact 1/10
May 15, 2026
Insider
BOURLA ALBERT sold 24 shares
Chairman & CEO @ $25.33 ($607.92)
Apr 23, 2026
Insider
Taraporevala Cyrus sold 7,686.539 shares
Director @ $26.67 ($205.0K)
Apr 16, 2026
SEC
CICC initiates PFE at Outperform with $33 PT — +15.6% upside vs. consensus mean
ANALYST-UPGRADE — Impact 3/10
Apr 16, 2026
SEC
Argus Research upgraded PFE from Hold to Buy with a $35 price target, representing 22.6% upside from the current $28.55.
ANALYST-UPGRADE — Impact 7/10
Price Targets
$29.19
+13.6% upside
Buy
Current $25.70
Low $24.00
Median $28.00
High $36.00
27 analysts
$24.00
$36.00
Analyst Ratings
6Strong Buy
9Buy
18Hold
2Sell
1Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 29, 2026 | Citigroup | MAINTAIN | Neutral → Neutral |
| Apr 20, 2026 | RBC Capital | REITERATE | Underperform → Underperform |
| Apr 16, 2026 | CICC | INITIATE | Outperform |
| Apr 13, 2026 | UBS | MAINTAIN | Neutral → Neutral |
| Apr 10, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight → Equal-Weight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.68 | $0.61 — $0.76 | -13% YoY | 18 |
| Next Q | $0.85 ▼ -0.6% | $0.65 — $0.96 | -3% YoY | 18 |
| Current FY | $2.96 | $2.80 — $3.12 | -8% YoY | 26 |
| Next FY | $2.84 | $2.43 — $3.10 | -4% YoY | 26 |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $13.5B | — |
| MORGAN STANLEY | $2.2B | — |
| NORGES BANK | $1.8B | NEW |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $1.3B | TRIM |
| BANK OF AMERICA CORP | $1.2B | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 29, 2026 | BOURLA ALBERT | A | $602.14 |
| May 15, 2026 | BOURLA ALBERT | A | $607.92 |
| Apr 23, 2026 | Taraporevala Cyrus | A | $205.0K |
| Apr 23, 2026 | Quincey James | A | $205.0K |
| Apr 23, 2026 | SMITH JAMES | A | $205.0K |
Reddit Sentiment
67°
Warm
Bearish
Neutral
Bullish
Congressional Trades
3 members: 3 buys, 0 sells
| Member | Party | Type | Amount |
|---|---|---|---|
| Ro Khanna | D | BUY | $1,001 - $15,000 |
| Gilbert Cisneros | D | BUY | $1,001 - $15,000 |
| Susan Collins | R | BUY | $15,001 - $50,000 |
12 institutional holders with $20.9B total value (840,965,876 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, NORGES. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 541,346,182 | $13.5B | 64.4% | — |
| 2 | MORGAN STANLEY | 89,113,604 | $2.2B | 10.6% | — |
| 3 | NORGES BANK | 73,533,577 | $1.8B | 8.7% | NEW |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 50,540,119 | $1.3B | 6.0% | TRIM -69.1% |
| 5 | BANK OF AMERICA CORP /DE/ | 48,781,192 | $1.2B | 5.8% | — |
| 6 | WELLS FARGO & COMPANY/MN | 18,768,836 | $467.3M | 2.2% | TRIM -26.9% |
| 7 | FMR LLC | 12,275,140 | $305.7M | 1.5% | ADD +26.6% |
| 8 | TWO SIGMA INVESTMENTS, LP | 2,152,508 | $53.6M | 0.3% | DOUBLED +2734.9% |
| 9 | Cullen Capital Management, LLC | 2,097,331 | $52.2M | 0.2% | TRIM -38.0% |
| 10 | CAUSEWAY CAPITAL MANAGEMENT LLC | 2,091,719 | $52.1M | 0.2% | — |
| 11 | Hillman Capital Management, Inc. | 175,304 | $4.4M | 0.0% | ADD +38.5% |
| 12 | DODGE & COX | 90,364 | $2.3M | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 73,533,577 | — | $1.8B | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 75,928 | 2,152,508 | +2734.9% | $53.6M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 3,395,558 | 0 | -100.0% | $0.00 | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 600,033 | 3,395,558 | +465.9% | $86.5M | 2025-Q3 |
| Cullen Capital Management, LLC | TRIM | 3,643,578 | 2,258,687 | -38.0% | $57.6M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 75,928 | — | $1.9M | 2025-Q3 |
| NORGES BANK | EXIT | 93,653,338 | 0 | -100.0% | $0.00 | 2025-Q3 |
| NORGES BANK | NEW | — | 93,653,338 | — | $2.3B | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | TRIM | 26,133,737 | 19,100,778 | -26.9% | $463.0M | 2025-Q2 |
| FMR LLC | ADD | 14,016,698 | 17,749,673 | +26.6% | $430.3M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 729,647 | 0 | -100.0% | $0.00 | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | TRIM | 155,459,101 | 48,029,575 | -69.1% | $1.2B | 2025-Q1 |
| FMR LLC | ADD | 10,756,020 | 14,016,698 | +30.3% | $355.2M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 752,024 | — | $19.1M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | NEAR_EXIT | 5,302,731 | 729,647 | -86.2% | $18.5M | 2025-Q1 |
| NORGES BANK | EXIT | 87,786,882 | 0 | -100.0% | $0.00 | 2025-Q1 |
| Hillman Capital Management, Inc. | ADD | 231,059 | 319,969 | +38.5% | $8.5M | 2024-Q4 |
| SOUND SHORE MANAGEMENT INC /CT/ | EXIT | 2,748,790 | 0 | -100.0% | $0.00 | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 130,143,942 | — | $3.8B | 2024-Q3 |
22 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 29, 2026 | BOURLA ALBERT | Chairman & CEO | A | 23 | $26.18 | $602.14 |
| May 15, 2026 | BOURLA ALBERT | Chairman & CEO | A | 24 | $25.33 | $607.92 |
| Apr 23, 2026 | Taraporevala Cyrus | Director | A | 7,686.539 | $26.67 | $205.0K |
| Apr 23, 2026 | Quincey James | Director | A | 7,686.539 | $26.67 | $205.0K |
| Apr 23, 2026 | SMITH JAMES C | Director | A | 7,686.539 | $26.67 | $205.0K |
| Apr 23, 2026 | NARAYEN SHANTANU | Director | A | 7,686.539 | $26.67 | $205.0K |
| Apr 23, 2026 | BLAYLOCK RONALD E | Director | A | 7,686.539 | $26.67 | $205.0K |
| Apr 23, 2026 | Buckley Mortimer J | Director | A | 7,686.539 | $26.67 | $205.0K |
| Apr 23, 2026 | Echevarria Joseph | Director | A | 7,686.539 | $26.67 | $205.0K |
| Apr 23, 2026 | Desmond-Hellmann Susan | Director | A | 7,686.539 | $26.67 | $205.0K |
| Apr 23, 2026 | NORA JOHNSON SUZANNE M | Director | A | 7,686.539 | $26.67 | $205.0K |
| Apr 23, 2026 | Gottlieb Scott | Director | A | 7,686.539 | $26.67 | $205.0K |
| Apr 23, 2026 | LITTMAN DAN R. | Director | A | 7,686.539 | $26.67 | $205.0K |
| Apr 15, 2026 | BOURLA ALBERT | Chairman & CEO | A | 22 | $27.19 | $598.18 |
| Apr 14, 2026 | BOURLA ALBERT | Chairman & CEO | A | 911 | $27.11 | $24.7K |
| Mar 31, 2026 | BOURLA ALBERT | Chairman & CEO | A | 21 | $28.08 | $589.68 |
| Mar 27, 2026 | Buckley Mortimer J | Director | A | 1,386.834 | $27.04 | $37.5K |
| Mar 27, 2026 | NARAYEN SHANTANU | Director | A | 1,849.112 | $27.04 | $50.0K |
| Mar 27, 2026 | Echevarria Joseph | Director | A | 1,710.429 | $27.04 | $46.3K |
| Mar 27, 2026 | Quincey James | Director | A | 1,433.062 | $27.04 | $38.7K |
| Mar 27, 2026 | SMITH JAMES C | Director | A | 1,664.201 | $27.04 | $45.0K |
| Mar 27, 2026 | Taraporevala Cyrus | Director | A | 1,386.834 | $27.04 | $37.5K |
| Mar 13, 2026 | BOURLA ALBERT | Chairman & CEO | A | 1,630 | $26.58 | $43.3K |
| Mar 4, 2026 | DAMICO JENNIFER B. | SVP & Controller | F | 826 | $26.62 | $22.0K |
| Mar 3, 2026 | DAMICO JENNIFER B. | SVP & Controller | A | 16,311 | $0.00 | $0.00 |
| Mar 3, 2026 | DAMICO JENNIFER B. | SVP & Controller | A | 22,638 | $0.00 | $0.00 |
| Mar 3, 2026 | de Germay Alexandre | Executive Vice President | A | 194,883 | $0.00 | $0.00 |
| Mar 3, 2026 | Denton David M | Chief Financial Officer & EVP | A | 216,537 | $0.00 | $0.00 |
| Mar 3, 2026 | SAHNI PAYAL | Executive Vice President | A | 108,268 | $0.00 | $0.00 |
| Mar 3, 2026 | Baum Andrew | Executive Vice President | A | 303,151 | $0.00 | $0.00 |
| Mar 3, 2026 | Fonseca Lidia | Executive Vice President | A | 82,284 | $0.00 | $0.00 |
| Mar 3, 2026 | LANKLER DOUGLAS M | Executive Vice President | A | 194,883 | $0.00 | $0.00 |
| Mar 3, 2026 | BOURLA ALBERT | Chairman & CEO | A | 708,666 | $0.00 | $0.00 |
| Mar 3, 2026 | McDermott Michael | Executive Vice President | A | 151,576 | $0.00 | $0.00 |
| Mar 3, 2026 | BOSHOFF CHRISTOFFEL | President, R&D | A | 259,844 | $0.00 | $0.00 |
| Mar 3, 2026 | MALIK AAMIR | Executive Vice President | A | 194,883 | $0.00 | $0.00 |
| Feb 27, 2026 | DAMICO JENNIFER B. | SVP & Controller | F | 655 | $27.65 | $18.1K |
| Feb 26, 2026 | McDermott Michael | Executive Vice President | F | 3,503 | $27.10 | $94.9K |
| Feb 25, 2026 | BOSHOFF CHRISTOFFEL | President, R&D | A | 13,383 | $0.00 | $0.00 |
| Feb 25, 2026 | SAHNI PAYAL | Executive Vice President | M | 56,888 | $33.82 | $1.9M |
| Feb 25, 2026 | Fonseca Lidia | Executive Vice President | M | 56,888 | $33.82 | $1.9M |
| Feb 25, 2026 | LANKLER DOUGLAS M | Executive Vice President | M | 122,907 | $33.82 | $4.2M |
| Feb 25, 2026 | DAMICO JENNIFER B. | SVP & Controller | M | 17,558 | $0.00 | $0.00 |
| Feb 25, 2026 | BOURLA ALBERT | Chairman & CEO | M | 491,626 | $33.82 | $16.6M |
| Feb 25, 2026 | Fonseca Lidia | Executive Vice President | M | 56,888 | $0.00 | $0.00 |
| Feb 25, 2026 | SAHNI PAYAL | Executive Vice President | M | 56,888 | $0.00 | $0.00 |
| Feb 25, 2026 | LANKLER DOUGLAS M | Executive Vice President | M | 122,907 | $0.00 | $0.00 |
| Feb 25, 2026 | DAMICO JENNIFER B. | SVP & Controller | M | 17,558 | $33.82 | $593.8K |
| Feb 25, 2026 | BOURLA ALBERT | Chairman & CEO | M | 491,626 | $0.00 | $0.00 |
| Feb 25, 2026 | McDermott Michael | Executive Vice President | M | 37,925 | $33.82 | $1.3M |
6 SEC filing reports analyzed. Sentiment: 3 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 3.2/10.
BULLISH
ANALYST-UPGRADE
7/10
Argus Research upgraded PFE from Hold to Buy with a $35 price target, representing 22.6% upside from
Apr 16, 2026
BULLISH
ANALYST-UPGRADE
3/10
CICC initiates PFE at Outperform with $33 PT — +15.6% upside vs. consensus mean
Apr 16, 2026
NEUTRAL
ANALYST-UPGRADE
1/10
Argus Research upgrades PFE to Buy — PT $35 (+35%) amid 8-firm cluster; consensus remains cautious
May 16, 2026
BULLISH
ANALYST-UPGRADE
2/10
CICC initiates PFE at Outperform with $33 PT (+27%) — a bullish call on a stock consensus largely rates as a Hold
May 16, 2026
NEUTRAL
8-K
4/10
Pfizer reported Q1 2026 Adjusted diluted EPS of $0.75, beating the $0.72 consensus by 4.2%, on reven
May 5, 2026
NEUTRAL
DEFA14A
2/10
Analysis based on filing metadata only — document content was unavailable
Mar 12, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Hold (42% buy). Based on 36 analysts: 6 strong buy, 9 buy, 18 hold, 2 sell, 1 strong sell.
Analyst Price Targets
$29.19 mean target
+13.6% upside
Buy (2.45)
$24.00 Low
$36.00 High
| Metric | Value |
|---|---|
| Current Price | $25.70 |
| Target Low | $24.00 |
| Target Mean | $29.19 |
| Target Median | $28.00 |
| Target High | $36.00 |
| # Analysts | 27 |
| Recommendation | Buy (2.45) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.68 | $0.61 | $0.76 | -12.8% | -0.4% | 6↑ 8↓ | $14.4B | -1.6% | 18 |
| Next Q 2026-09-30 |
$0.85 | $0.65 | $0.96 | -2.5% | -0.6% | 7↑ 7↓ | $16.1B | -3.0% | 18 |
| Current FY 2026-12-31 |
$2.96 | $2.80 | $3.12 | -8.0% | -0.2% | 11↑ 8↓ | $61.7B | -1.4% | 26 |
| Next FY 2027-12-31 |
$2.84 | $2.43 | $3.10 | -4.2% | -0.5% | 12↑ 7↓ | $59.3B | -3.8% | 26 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.680 | |
| 7d ago | $0.680 | |
| 30d ago | $0.683 | -0.003 |
| 60d ago | $0.687 | -0.006 |
| 90d ago | $0.702 | -0.021 |
12 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 3 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 29, 2026 | Citigroup | MAINTAIN | Neutral | Neutral |
| Apr 20, 2026 | RBC Capital | REITERATE | Underperform | Underperform |
| Apr 16, 2026 | CICC | INITIATE | — | Outperform |
| Apr 13, 2026 | UBS | MAINTAIN | Neutral | Neutral |
| Apr 10, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | Equal-Weight |
| Apr 9, 2026 | B of A Securities | MAINTAIN | Neutral | Neutral |
| Mar 24, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Mar 17, 2026 | HSBC | MAINTAIN | Buy | Buy |
| Mar 2, 2026 | Argus Research | UPGRADE | Hold | Buy |
| Feb 25, 2026 | RBC Capital | INITIATE | — | Underperform |
| Feb 20, 2026 | Barclays | INITIATE | — | Underweight |
| Feb 9, 2026 | Freedom Broker | MAINTAIN | Buy | Buy |
| Feb 4, 2026 | Cantor Fitzgerald | REITERATE | Neutral | Neutral |
| Jan 27, 2026 | Cantor Fitzgerald | MAINTAIN | Neutral | Neutral |
| Dec 17, 2025 | Morgan Stanley | MAINTAIN | Equal-Weight | Equal-Weight |
| Dec 15, 2025 | B of A Securities | MAINTAIN | Neutral | Neutral |
| Dec 12, 2025 | Morgan Stanley | MAINTAIN | Equal-Weight | Equal-Weight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 9 | 18 | 2 | 1 | 42% | |
| May 1, 2026 | 5 | 11 | 17 | 2 | 1 | 44% | |
| Apr 1, 2026 | 6 | 9 | 17 | 2 | 1 | 43% | |
| Mar 1, 2026 | 5 | 9 | 18 | 2 | 1 | 40% | |
| Feb 1, 2026 | 5 | 10 | 17 | 0 | 1 | 45% | |
| Jan 1, 2026 | 5 | 10 | 17 | 0 | 1 | 45% |
Strong BuyBuyHoldSellStrong Sell
3 members of Congress traded this stock: 3 buys, 0 sells.
Congressional Trades
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Apr 13, 2026 | Ro Khanna | D | HOUSE | BUY | $1,001 - $15,000 | Pfizer Inc | May 13, 2026 (31d) |
| Feb 10, 2026 | Gilbert Cisneros | D | HOUSE | BUY | $1,001 - $15,000 | Pfizer Inc | Mar 10, 2026 (29d) |
| Feb 3, 2026 | Susan Collins | R | SENATE | BUY | $15,001 - $50,000 | Pfizer Inc | Mar 26, 2026 (51d) |
67°
Warm
Bearish
Neutral
Bullish
2 mentions
2 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 19, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 19, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
The best stock to buy: $BWXT
▲ 1
💬 0
⚡ 0.5
Calls on Pfizer (PFE) - Good Margin of Safety
▲ 1
💬 1
⚡ 0.0
Aug 17, 2026
fda_pdufa
PDUFA: PFE — Padcev in muscle-invasive bladder cancer (MIBC) — 2026-08-17
FDA target action date 2026-08-17 for PFE (PFIZER INC). Drug: Padcev. Indication: muscle-invasive bladder cancer (MIBC). FDA set PDUFA target action d
Jun 10, 2026
Clinical Trial
Respiratory Effect of the LISA Method With Sedation by Propofol Versus Absence of Sedation.
Phase Phase 3 — COMPLETED
Jun 9, 2026
Clinical Trial
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET
Phase Phase 3 — COMPLETED
Jun 6, 2026
Clinical Trial
A Clinical Trial to Evaluate the Safety and Efficacy of Ciprofloxacin in the Treatment of Plague in Humans
Phase Phase 2 — COMPLETED
Jun 4, 2026
FDA
Premarin
WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER and PROBABLE DEMENTIA WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREA
Jun 3, 2026
Clinical Trial
Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15
Phase Phase 2 — COMPLETED
Jun 3, 2026
Clinical Trial
Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer
Phase Phase 2 — COMPLETED
Jun 3, 2026
clinical_trial_readout
T-90d Trial Readout: ARV-471 (Phase 2)
Trial: TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Brea
Jun 1, 2026
clinical_trial_readout
T-90d Trial Readout: PF-07220060 + PF-07104091 combination dose escalation (Phase 2)
Trial: A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tum
Jun 1, 2026
short_volume
Short Volume: PFE — 55.4% short (8.9M / 16.0M)
Short: 8,875,058 | Exempt: 57,210 | TRF Vol: 16,014,448 | Short Ratio: 55.4% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
FDA
Sufentanil Citrate
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF SUFENTANIL CITRATE INJECTION Addiction, Abuse, and Misuse Because the use of Sufentanil Citra
May 29, 2026
FDA
Marcaine
WARNING: RISK OF CARDIAC ARREST WITH USE OF MARCAINE IN OBSTETRICAL ANESTHESIA There have been reports of cardiac arrest with difficult resuscitation
May 27, 2026
clinical_trial_readout
Results Pending: Carboplatin (Phase 2) — Completed 48d ago
Trial: Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.
Sponsor: Cantargia AB
Pha
May 27, 2026
FDA
Litfulo
WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOSIS WARNING: SERIOUS INFECTIONS, MORTALITY,
May 25, 2026
clinical_trial_readout
T-90d Trial Readout: PF-07220060 + PF-07104091 combination dose escalation (Phase 2)
Trial: A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tum
May 23, 2026
FDA
MIDAZOLAM
WARNINGS Personnel and Equipment for Monitoring and Resuscitation Adults and Pediatrics : Intravenous midazolam has been associated with respiratory d
May 18, 2026
dark_pool
Dark Pool: PFE — 26.8M shares, 175,041 trades
Week starting 2026-05-18. Total ATS volume: 26,800,654 shares across 175,041 trades.
May 13, 2026
clinical_trial_readout
Results Pending: Irinotecan (Phase 3) — Completed 33d ago
Trial: Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Smal
May 11, 2026
dark_pool
Dark Pool: PFE — 23.4M shares, 175,172 trades
Week starting 2026-05-11. Total ATS volume: 23,431,429 shares across 175,172 trades.
May 8, 2026
short_interest
FTD: PFE — 35,039 shares ($0.9M) failed to deliver
Settlement: 20260508, Price: $26.48, FTD Value: $927,832.72, PFIZER INC;COM USD0.05
May 7, 2026
short_volume
Short Volume: PFE — 56.2% short (11.7M / 20.8M)
Short: 11,688,209 | Exempt: 61,638 | TRF Vol: 20,789,801 | Short Ratio: 56.2% | Off-exchange volume (dark pool + OTC)
May 7, 2026
short_interest
FTD: PFE — 99,658 shares ($2.6M) failed to deliver
Settlement: 20260507, Price: $26.53, FTD Value: $2,643,926.74, PFIZER INC;COM USD0.05
May 5, 2026
earnings_calendar
PFE Q1 2026 Earnings Scheduled — 2026-05-05
May 4, 2026
dark_pool
Dark Pool: PFE — 34.0M shares, 200,340 trades
Week starting 2026-05-04. Total ATS volume: 33,956,050 shares across 200,340 trades.
May 1, 2026
clinical_trial_readout
Results Pending: brentuximab vedotin (Phase 2) — Completed 87d ago
Trial: Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Phase: Phase 2 | Complet